Capital One Financial Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $26
Promising Potential of Olema Pharmaceuticals' Palazestrant and KAT6 Inhibitor Fuels Buy Rating
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
Buy Rating for Olema Pharmaceuticals: Promising Preclinical Data and Strategic Pipeline Synergy
Olema Oncology Highlights Presentation Of Preclinical Data Demonstrating Anti-Tumor Activity For OP-3136
Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Olema Pharmaceuticals Will Be Presenting Multiple Posters During The EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics (ENA 2024)
Express News | Olema Oncology Announces New Preclinical Combination Data to Be Presented at the 2024 Eortc-Nci-AACR Symposium on Molecular Targets and Cancer Therapeutics
Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Raises Target Price to $27
Goldman Sachs analyst Richard Law CFA maintains $Olema Pharmaceuticals(OLMA.US)$ with a buy rating, and adjusts the target price from $24 to $27.According to TipRanks data, the analyst has a success
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $31
Express News | Olema Pharmaceuticals Inc : JP Morgan Cuts Target Price to $31 From $33
Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $30 Price Target
Olema Pharmaceuticals Analyst Ratings
Buy Rating Reaffirmed for Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strong Financials
Buy Rating Affirmed for Olema Pharmaceuticals Amidst Promising Clinical Developments and Strategic Collaborations
Olema Pharmaceuticals GAAP EPS of -$0.54 Beats by $0.01
Olema Pharmaceuticals | 10-Q: Q2 2024 Earnings Report